5247422025-04-012025-06-305247422025-06-305247422025-04-012025-06-30in-capmkt:OtherExpenses1Member5247422025-04-012025-06-30in-capmkt:ReportableSegments1Member5247422025-04-012025-06-30in-capmkt:ReportableSegments2Member5247422025-04-012025-06-30in-capmkt:ReportableSegments3Member5247422025-04-012025-06-30in-capmkt:ReportableSegments1Member5247422025-04-012025-06-30in-capmkt:ReportableSegments2Member5247422025-04-012025-06-30in-capmkt:ReportableSegments3Member5247422025-04-012025-06-30in-capmkt:ReportableSegments1Member5247422025-06-30in-capmkt:ReportableSegments1Member5247422025-04-012025-06-30in-capmkt:ReportableSegments2Member5247422025-06-30in-capmkt:ReportableSegments2Member5247422025-04-012025-06-30in-capmkt:ReportableSegments3Member5247422025-06-30in-capmkt:ReportableSegments3Member5247422025-04-012025-06-30in-capmkt:ReportableSegments1Member5247422025-06-30in-capmkt:ReportableSegments1Member5247422025-04-012025-06-30in-capmkt:ReportableSegments2Member5247422025-06-30in-capmkt:ReportableSegments2Member5247422025-04-012025-06-30in-capmkt:ReportableSegments3Member5247422025-06-30in-capmkt:ReportableSegments3Member5247422025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524742CAPLIPOINTNOTLISTEDINE475E01026CAPLIN POINT LABORATORIES LIMITEDMain BoardEquity2025-04-012026-03-312025-08-072025-07-30INRCroresQuarterlyFirst quarterGeographical2025-08-0711:10:002025-08-0712:45:00Not applicable2025-04-012025-06-30UnauditedConsolidated51022000002314000005333600000735100000113500000082300000431600000180000016290000094060000034893000001844300000018443000003310000006000000337000000015073000000003000001507600000360000015112000001528000000-204000001531600000-20400000152000000220.120.030020.120.03Consolidated Notes: <BR> 1) The above Unaudited Consolidated financial Results for the Quarter ended June 30, 2025 were recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 7, 2025. The Statutory Auditors have carried out a limited review on the unaudited standalone financial results and issued unmodified report thereon. <BR> <BR> 2) The Unaudited Consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (the Act) read with relevant rules issued thereunder (Ind AS) and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). <BR> <BR> 3) The Group has identified two geographical segments as its reportable segments in accordance with Ind AS 108 – Operating Segments. Segment 1: Rest of the World. Segment 2: United States of America (USA) Accordingly, segment reporting has been presented along with the Consolidated results. <BR> <BR> 4) As regards the pending Insurance claim, the matter is currently pending before legal forum which will be dealt with appropriately upon reaching the finality. Accordingly, CSL will continue to recognize the insurance claim as recoverable. <BR> <BR> 5) During the quarter ended June 30, 2025 and March 31, 2025 the Company had allotted NIL equity shares of Rs. 2 each under the Employees Stock Option Schemes and the total number of equity shares of the Company stands at 7,60,11,696 as at June 30, 2025. The Company had allotted 68,550 equity shares during the quarter ended June 30, 2024. <BR> <BR> 6) During the quarter ended June 30, 2025 the Companys wholly owned Subsidiary Caplin Point Far East Limited, Hong Kong has acquired 100 percent shares of Neo Ethicals Chile SpA with effect from 1st April, 2025 and Triwin Pharma S.A DE C.V (Mexico) with effect from 3rd June, 2025. The results of both these Step down subsidiaries have been Consolidated in the current quarter results. <BR> <BR> 7) The Board of Directors at their meeting held on 15th May, 2025 declared an interim dividend of Rs. 3.00 (Rs. Three Only) per equity share (150 percent) for the financial year 2024-25 and was paid to the shareholders on 9th June 2025. The Board of Directors at their meeting held today have recommended a final dividend of Rs. 3 per equity share (150 percent) for the financial year 2024-25 which is subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company. <BR> <BR> The total dividend for the financial year 2024-25 including the final dividend (subject to the approval of the Shareholders at the ensuing Annual General Meeting) will be Rs. 6 per equity share (300 percent) of the face value of Rs. 2 each. <BR> <BR> 8) Previous periods figures have been regrouped/reclassified to be in conformity with current period's classification/ disclosure, wherever necessary. <BR> Other Expenses940600000Rest of the World4035300000USA1066900000Unallocated231400000533360000005333600000Rest of the World1514600000USA98600000Unallocated2314000001844600000001844600000Rest of the World14888000000USA5871900000Unallocated1236990000033129800000033129800000Rest of the World2493100000USA503400000Unallocated02996500000029965000000Exchange difference in translating the financial statements of foreign operations3600000360000003600000